rs10033464 — KCNN3 KCNN3 AF susceptibility variant

The Atrial Fibrillation Switch at 4q25 — Why This Locus Reshapes Your AF Risk

On chromosome 4, near the 25th megabase, sits a cluster of variants that have proven to be among the strongest common genetic determinants of atrial fibrillation (AF) ever discovered. rs10033464 is one of two independently acting signals at this locus, positioned close to both KCNN3 — encoding the small-conductance calcium-activated potassium channel SK3¹¹ small-conductance calcium-activated potassium channel SK3
SK channels regulate atrial repolarization and the refractory period; their dysregulation is mechanistically linked to re-entry arrhythmias — and PITX2, a transcription factor essential for left-right heart asymmetry. Carrying even one copy of the T allele meaningfully raises your lifetime AF risk and, crucially, predicts how well your heart responds to rhythm-control therapies.

The Mechanism

Although rs10033464 falls in a region that does not encode protein, its functional impact on atrial tissue is real. The 4q25 locus likely acts through regulatory effects on PITX2 and KCNN3 expression in the pulmonary vein sleeves and left atrial myocardium²² The 4q25 locus likely acts through regulatory effects on PITX2 and KCNN3 expression in the pulmonary vein sleeves and left atrial myocardium
Regulatory variants can alter transcription factor binding sites, enhancers, and promoter accessibility without changing any amino acid sequence. PITX2 suppresses a default program that would otherwise generate an extra, right-sided sinus node in the left atrium — when PITX2 is downregulated, ectopic firing foci multiply and the substrate for AF is established. SK3 channels, encoded by KCNN3, shape the atrial [action potential | the electrical cycle that triggers each heartbeat] repolarization phase. When SK3 activity is altered, the effective refractory period shortens, making re-entry circuits — the electrical loops that sustain AF — easier to initiate and harder to terminate.

Crucially, rs10033464 represents a second, independent signal at 4q25, distinct from the primary rs2200733 variant. Carrying T alleles at both positions compounds the risk beyond either alone.

The Evidence

The locus was first implicated in AF by Gudbjartsson et al. 2007³³ Gudbjartsson et al. 2007
Genome-wide association study in Icelandic and European populations; replicated in Chinese cohort from Hong Kong (Nature), which identified two 4q25 variants conferring OR ~1.72 and ~1.39 per copy in Europeans. This was one of the first GWAS discoveries in cardiac arrhythmia genetics and established 4q25 as the most replicated AF locus in the literature.

Beyond AF susceptibility, Gretarsdottir et al. 2008⁴⁴ Gretarsdottir et al. 2008 (Ann Neurol) demonstrated that rs10033464 also significantly associates with cardioembolic ischemic stroke (OR 1.27, p=6.1×10⁻⁴ across >5,000 cases), most likely because undetected paroxysmal AF allows clot formation in the fibrillating left atrium. AF that is never clinically diagnosed can still produce embolic strokes — and the 4q25 genotype appears to be a marker for this occult pathway.

The variant also predicts treatment outcomes. Parvez et al. 2012⁵⁵ Parvez et al. 2012 (JACC, n=478 + 198 replication) showed that GG homozygotes had dramatically better responses to antiarrhythmic drugs — OR 4.7 in discovery (p=0.0013) and OR 1.5 in replication (p=0.04). For catheter ablation, a meta-analysis by He et al. 2018⁶⁶ meta-analysis by He et al. 2018 (n=2,145 ablation patients) found T-allele carriers had OR 1.51 for AF recurrence post-procedure. An updated meta-analysis by Jiang et al. 2019⁷⁷ updated meta-analysis by Jiang et al. 2019 across nine studies (n=3,204) confirmed TT homozygotes had 1.52× higher odds of recurrence than GG homozygotes (p=0.002).

Practical Actions

Carriers of the T allele should prioritize continuous cardiac monitoring for AF detection — particularly single-lead ECG patches worn for weeks rather than a standard 24-hour Holter, given the paroxysmal nature of early AF. When AF is diagnosed, the GG → TG/TT gradient in antiarrhythmic drug response is clinically actionable: T-allele carriers have lower odds of rhythm-control success and should discuss with their cardiologist whether rate-control first or early catheter ablation is preferred over serial drug trials. Ablation is more likely to be first-line rather than last-resort for this genotype.

Post-ablation, T-allele carriers face higher recurrence rates, so extended rhythm surveillance (30-day patch monitors at 3, 6, and 12 months) rather than symptom-driven follow-up is warranted.

Interactions

rs10033464 acts independently of, but additively with, the primary 4q25 signal rs2200733. Individuals carrying T alleles at both variants (compound risk at 4q25) have substantially higher AF risk than either alone — a compound action covering this combination is proposed in the harvesting notes below. There is also emerging evidence that the AF-promoting effect of rs10033464 is amplified in the presence of obstructive sleep apnea, where hypoxia-induced atrial remodeling interacts with the genotypically shortened refractory period.